Concert Pharmaceuticals` Roger Tung Awarded 2009 Mass High Tech All Star Award

LEXINGTON, Mass.--(Business Wire)--
Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President
and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for
his contributions to the pharmaceutical industry. The annual All Star awards
honor pioneers and leaders across several business and technology sectors in New
England. This year`s honorees will be profiled in a special supplement in the
November 4 edition of Mass High Tech: The Journal of New England Technology.

"Roger has become a true leader in the biotech community and is a very deserving
recipient of this award. As a scientist, he has a remarkable track record of
discovering and developing novel drugs for diseases such as HIV, Hepatitis C,
and cystic fibrosis. While building on that success at Concert, he has also
proven to be a terrific entrepreneur, leading a fast growing and exciting new
company," said Richard H. Aldrich, Chairman of the Board of Concert
Pharmaceuticals.

"I am honored to be recognized by Mass High Tech with this award," said Dr.
Roger Tung. "This award is a tribute to all of Concert`s employees who are
advancing a new branch of chemistry that we believe will enable the rapid
discovery and development of clinically and commercially important new
medicines."

Roger Tung has served as President and Chief Executive Officer of Concert
Pharmaceuticals, Inc. since he co-founded the company in 2006 based on his
independent scientific research. After more than 20 years in drug discovery, Dr.
Tung decided to take a different approach to pharmaceutical discovery and
development. His vision is to create differentiated, important new medicines
while reducing the risk, expense, and long timelines associated with traditional
drug development. This vision is embodied by Concert`s technology platform which
involves the selective incorporation of deuterium atoms in place of hydrogen in
compounds with proven human pharmacological activity in order to improve their
metabolism and pharmacokinetics. This process can provide novel drugs that
retain the pharmacological activity of the starting compounds but that, in
favorable cases, can possess substantially improved safety and/or efficacy
features.

A medicinal chemist by training, Dr. Tung was previously at Vertex
Pharmaceuticals from 1989, when he joined as a founding scientist, until 2005.
At Vertex he co-invented their two commercial HIV protease inhibitors (Lexiva
and Agenerase). Dr. Tung also oversaw the discovery of clinical candidates for a
wide range of therapeutic targets including HIV protease, IMPDH, p38 MAP kinase,
HCV protease, HDAC, and CFTR at both protein and transcriptional levels.

Dr. Tung received his Ph.D. in medicinal chemistry at the University of
Wisconsin-Madison and his B.A. degree in Chemistry from Reed College. He is
currently an advisor to the Chinese-American BioMedical Association and a
Scientific Advisor for Medivation, Inc.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on the
application of deuterium chemistry to create novel and differentiated small
molecule drugs. Concert`s approach leverages known activity and safety of
existing drugs to reduce time, risk and expense of drug research and
development. The Company has a broad research pipeline encompassing many
therapeutic areas including infectious disease and renal disease, among others.
Its lead development candidate is the HIV protease inhibitor CTP-518. In 2009,
Concert entered into a potential $1 billion collaboration with GlaxoSmithKline
to develop and commercialize certain deuterium-containing medicines. Founded in
2006, Concert has raised more than $110 million of venture and institutional
capital. For more information on Concert Pharmaceuticals, please visit
www.concertpharma.com.

Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert
Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc.
Justine Koenigsberg (investors), 781-674-5284
or
Yates Public Relations
Kathryn Morris (media), 845-635-9828

Copyright Business Wire 2009